These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 18363814)

  • 21. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors.
    Ingerslev J
    Semin Thromb Hemost; 2000; 26(4):425-32. PubMed ID: 11092219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant factor VIIa: a review on its clinical use.
    Franchini M
    Int J Hematol; 2006 Feb; 83(2):126-38. PubMed ID: 16513530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant factor VIIa: its background, development and clinical use.
    Hedner U
    Curr Opin Hematol; 2007 May; 14(3):225-9. PubMed ID: 17414211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Articular Bleeding in Hemophilia.
    Rodriguez-Merchan EC
    Cardiovasc Hematol Disord Drug Targets; 2016; 16(1):21-24. PubMed ID: 28049407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2007; 25(12):1007-29. PubMed ID: 18047387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors.
    Stephens JM; Joshi AV; Sumner M; Botteman MF
    Expert Opin Pharmacother; 2007 Jun; 8(8):1127-36. PubMed ID: 17516876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemophilic synovitis: factor VII and the potential role of extravascular factor VIIa.
    Monahan PE; Sun J
    Thromb Res; 2010 Apr; 125 Suppl 1():S63-6. PubMed ID: 20227556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings.
    Grounds RM; Bolan C
    Crit Care; 2005; 9 Suppl 5(Suppl 5):S29-36. PubMed ID: 16221317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant human factor VIIa and a factor VIIa-analogue reduces heparin and low molecular weight heparin (LMWH)-induced bleeding in rats.
    Lauritzen B; Hedner U; Johansen PB; Tranholm M; Ezban M
    J Thromb Haemost; 2008 May; 6(5):804-11. PubMed ID: 18315554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant factor VIIa in the treatment of bleeding in hemophilic children with inhibitors.
    Shapiro AD
    Semin Thromb Hemost; 2000; 26(4):413-9. PubMed ID: 11092217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents.
    Goldstein B; Geldziler B; Bjerre J; Seremetis S
    Transfus Apher Sci; 2008 Feb; 38(1):25-32. PubMed ID: 18267372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant FVIIa in the treatment of bleeding in acquired hemophilia.
    Guerin V; Chossat I; Dutronc H; Dubreuil M; Valentin F
    Am J Hematol; 2002 Aug; 70(4):333. PubMed ID: 12210820
    [No Abstract]   [Full Text] [Related]  

  • 33. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
    Mehta DA; Oladapo AO; Epstein JD; Novack AR; Neufeld EJ; Hay JW
    J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
    Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
    Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo effect of rFVIII and rFVIIa in hemophilia A rats evaluated by the Tail Vein Transection Bleeding Model.
    Stagaard R; Øvlisen GO; Klæbel JH; Danielsen D; Lund A; Elm T; Ley CD
    J Thromb Haemost; 2023 May; 21(5):1189-1199. PubMed ID: 36696187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The concept of recombinant factor VIIa megadose for treating bleeding episodes in high-titer inhibitor patients with hemophilia: toward an expanding indication?
    Negrier C
    J Thromb Haemost; 2003 Mar; 1(3):423-4. PubMed ID: 12871444
    [No Abstract]   [Full Text] [Related]  

  • 37. Successful hemostasis during a major orthopedic operation by using recombinant activated factor VII in a patient with severe hemophilia A and a potent inhibitor.
    O'Marcaigh AS; Schmalz BJ; Shaughnessy WJ; Gilchrist GS
    Mayo Clin Proc; 1994 Jul; 69(7):641-4. PubMed ID: 8015327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Promising coagulation factor VIII bypassing strategies for patients with haemophilia A.
    Duan X; Tang M; Zhang J; Yu H; Xu R
    Blood Coagul Fibrinolysis; 2014 Sep; 25(6):539-52. PubMed ID: 24614429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patients.
    Ng HJ; Lee LH
    Vasc Health Risk Manag; 2006; 2(4):433-40. PubMed ID: 17323597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia.
    Allen GA; Persson E; Campbell RA; Ezban M; Hedner U; Wolberg AS
    Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):683-9. PubMed ID: 17204663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.